Research Topic: fungal biomarkers

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19 infection, a fungal marker called beta-D-glucan (BDG) in the blood can predict patient survival even without a diagnosed fungal infection. Researchers found that COVID-19 patients with high BDG levels had a 91% death rate if not treated with antifungal drugs, but this dropped to 50% when antifungal therapy was given. The high BDG levels trigger a strong inflammatory response in the body that worsens disease severity, making BDG a valuable warning sign for doctors treating critically ill COVID-19 patients.

Read More »

Diagnostic performance of Aspergillus-specific immunoglobulin G immunochromatographic and enzyme-linked immunosorbent assay testing in chronic pulmonary aspergillosis: comparative analysis across subtypes and influencing factors

mycolabadmin

Chronic pulmonary aspergillosis is a serious fungal lung infection that often develops after tuberculosis. This study compared two blood tests for diagnosing this disease: a quick point-of-care test and a traditional lab test. The quick test performed better overall and could be used in areas without advanced laboratory equipment, though previous antifungal or steroid medications can reduce its effectiveness.

Read More »

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Read More »

Diagnostic Approaches to Invasive Candidiasis: Challenges and New Perspectives

mycolabadmin

Invasive candidiasis is a dangerous fungal infection affecting critically ill hospital patients. Current testing methods like blood cultures are slow and unreliable, so doctors are developing faster tests using DNA detection and biomarkers. A combination of new diagnostic tools and prompt treatment with antifungal medications is essential to improve survival rates and reduce complications from this serious infection.

Read More »
Scroll to Top